Positions

Overview

  • Dr. Jeffrey R Curtis is a Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). Dr. Curtis received a Medical Degree (MD) and a Master of Public Health (MPH) degree from Oregon Health & Sciences University in Portland, OR. He subsequently completed a residency in internal medicine at Oregon Health & Science University and a fellowship in rheumatology at UAB. He completed a graduate program in Clinical Informatics at Stanford University and received his Master of Science (MS) degree in epidemiology at the Harvard School of Public Health. He is board certified in both rheumatology and clinical informatics. Dr. Curtis currently holds the Marguerite Jones Harbert – Gene V. Ball Endowed Professorship in Rheumatology and Immunology at UAB. He is the Co-Director of the UAB Pharmacoepidemiology and Pharmacoeconomics Research (PEER) Unit. PEER uses multiple large data sources to study comparative effectiveness questions across multiple chronic diseases. These data sources include national administrative data from Medicare and commercial health plans, electronic health record data, and large registries. In 2012, he was awarded the Henry Kunkel Young Investigator Award by the American College of Rheumatology (ACR) and was accepted into the American Society for Clinical Investigation (ASCI) in 2016. The evaluation of the efficacy, comparative effectiveness, and safety of the medications used to treat rheumatoid arthritis and spondyloarthritis are among Dr. Curtis’s research interests. He served on the Core Expert Panel for the ACR’s 2008, 2012, and 2015 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA. He was the Deputy Director for a collaborative project between the FDA, the Agency for Healthcare Research and Quality (AHRQ), and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources. He is the Co-PI of the PCORI-funded Patient Powered Research Network “Arthritis-Power” registry, focused on RA, psoriasis, and psoriatic arthritis. He also leads the multi-center NIH-funded large pragmatic randomized controlled trial “VERVE” studying the safety and effectiveness of the live herpes zoster vaccine in patients receiving biologic agents. He is a member of the Center for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) Herpes Zoster workgroup. In 2015, he was appointed as a member to the FDA Arthritis Advisory Committee. Dr. Curtis also studies risk factors for and outcomes of osteoporosis. He was a member of the ACR’s task force to update recommendations for the management of glucocorticoid induced osteoporosis (GIOP). He served on the ASBMR Task Force on Atypical Subtrochanteric and Diaphyseal Fractures. Dr. Curtis is a member of the American College of Rheumatology (ACR), the International Society for Pharmacoepidemiology (ISPE), the American Medical Informatics Association (AMIA), and the American Society of Bone and Mineral Research (ASBMR). He has been on the editorial board for Arthritis & Rheumatism, Pharmacoepidemiology and Drug Safety (PDS) and Arthritis Care and Research (AC&R). He has authored more than 400 peer-reviewed manuscripts, review articles and book chapters.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Anti-TNF and Physiologic Measures of Metabolic Disease in Rheumatoid Arthritis.JCR: Journal of Clinical Rheumatology.  25:e54-e56. 2019
    2019 Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients.Arthritis Care and Research.  71:1004-1018. 2019
    2019 Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis.European Respiratory Journal.  54. 2019
    2019 The promise and perils of 'Big Data': focus on spondyloarthritisCurrent Opinion in Rheumatology.  31:355-361. 2019
    2019 Comparison of an interactive voice response system and smartphone application in the identification of gout flaresArthritis Research.  21. 2019
    2019 Risk of biologics and glucocorticoids in patients with rheumatoid arthritis undergoing arthroplasty a cohort studyAnnals of Internal Medicine.  170:825-836. 2019
    2019 A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid ArthritisPharmacoEconomics.  37:829-843. 2019
    2019 Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritisRheumatology.  58:874-883. 2019
    2019 Digital Interventions to Build a Patient Registry for Rheumatology ResearchRheumatic Disease Clinics of North America.  45:173-186. 2019
    2019 Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: A pooled analysis of 11 317 patients across clinical trialsRMD Open.  5. 2019
    2019 Opioid use in rheumatoid arthritis: trends, efficacy, safety, and best practicesCurrent Opinion in Rheumatology.  31:264-270. 2019
    2019 The Interface Between Digital Health and RheumatologyRheumatic Disease Clinics of North America.  45:xv-xvi. 2019
    2019 Tools and Methods for Real-World Evidence Generation: Pragmatic Trials, Electronic Consent, and Data LinkagesRheumatic Disease Clinics of North America.  45:275-289. 2019
    2019 Toward relevant and credible cost-effectiveness analyses for value assessment in the decentralized U.S. health care systemJournal of Managed Care && Speciality Pharmacy.  25:518-521. 2019
    2019 Patient- and Rheumatologist- Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis.Arthritis Care and Research2019
    2019 Data linkages between patient-powered research networks and health plans: A foundation for collaborative researchJournal of the American Medical Informatics Association.  26:594-602. 2019
    2019 Improved Quality of Life with Anti-TNF Therapy Compared with Continued Corticosteroid Utilization in Crohn's DiseaseInflammatory Bowel Diseases.  25:925-936. 2019
    2019 Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension studyArthritis Research.  21. 2019
    2019 Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United StatesCurrent Medical Research and Opinion.  35:603-609. 2019
    2019 Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United StatesCurrent Medical Research and Opinion.  35:611-617. 2019
    2019 Contraception methods used by women with rheumatoid arthritis and psoriatic arthritisClinical Rheumatology.  38:1207-1212. 2019
    2019 Validity of Privacy-Protecting Analytical Methods That Use only Aggregate-Level Information to Conduct Multivariable-Adjusted Analysis in Distributed Data NetworksAmerican Journal of Epidemiology.  188:709-723. 2019
    2019 Assessing RA Disease Activity with PROMIS Measures using Digital Technology.Arthritis Care and Research2019
    2019 Comparative Risk of Cardiovascular Events with Biologic and Synthetic Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.Arthritis Care and Research2019
    2019 Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized TrialAmerican Journal of Medicine.  132:354-361. 2019
    2019 Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States.Journal of Rheumatology.  46:237-244. 2019
    2019 PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis.Journal of Patient-Reported Outcomes.  3:14. 2019
    2019 Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scoresClinical Rheumatology.  38:437-445. 2019
    2019 A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator TrialsArthritis Care and Research.  71:319-322. 2019
    2019 Response to: 'Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?' by Suyama and OkadaAnnals of the Rheumatic Diseases.  78. 2019
    2019 Risk of subsequent fracture after prior fracture among older womenOsteoporosis International.  30:79-92. 2019
    2019 Direct-acting antivirals for hepatitis C: Predictors of early discontinuation in the real worldJournal of Managed Care && Speciality Pharmacy.  25:697-704. 2019
    2019 Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritisPLoS ONE.  14. 2019
    2019 Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilarsPharmacoepidemiology and Drug Safety2019
    2019 Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient-Reported Outcome Data Collection: A Qualitative StudyArthritis Care and Research.  71:80-87. 2019
    2019 Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studiesCurrent Medical Research and Opinion2019
    2019 Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitorJournal of Rheumatology.  46:475-482. 2019
    2019 Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative OutcomesArthritis Care and Research2019
    2018 Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014Chest.  154:1311-1320. 2018
    2018 Diet and exercise changes following bone densitometry in the Patient Activation After DXA Result Notification (PAADRN) studyArchives of Osteoporosis.  13. 2018
    2018 Importance of Recent Fracture as Predictor of Imminent Fracture RiskCurrent Osteoporosis Reports.  16:738-745. 2018
    2018 Screening of Hyperlipidemia among Patients with Rheumatoid Arthritis in the United States.Arthritis Care and Research2018
    2018 Correction to: Hip fracture trends in the United States, 2002 to 2015 (Osteoporosis International, (2018), 29, 3, (717-722), 10.1007/s00198-017-4345-0)Osteoporosis International.  29:2583. 2018
    2018 Is Rheumatoid Arthritis a Cardiovascular Risk-Equivalent to Diabetes Mellitus?Arthritis Care and Research.  70:1694-1699. 2018
    2018 The International Consortium for Health Outcome Measurement (ICHOM)Set of Outcomes that Matter to People Living with Inflammatory Arthritis Consensus from an international Working Group.Arthritis Care and Research2018
    2018 Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.Arthritis Care and Research2018
    2018 Evaluation of a Methodologic Approach to Define an Inception Cohort of Rheumatoid Arthritis Patients Using Administrative DataArthritis Care and Research.  70:1541-1545. 2018
    2018 Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected ConditionsJournal of Bone and Mineral Research.  33:1881-1888. 2018
    2018 Patient Governance in a Patient-Powered Research Network for Adult Rheumatologic ConditionsMedical Care.  56:S16-S21. 2018
    2018 Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort StudyArthritis and Rheumatology.  70:1565-1571. 2018
    2018 Low Persistence Rates in Rheumatoid Arthritis Patients Treated with Triple Therapy are Attributed to Adverse Drug Events Associated with Sulfasalazine.Arthritis Care and Research2018
    2018 A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and ConsequencesAdvances in Therapy.  35:1333-1355. 2018
    2018 Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritisQuality of Life Research.  27:2443-2451. 2018
    2018 Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional studyClinical Rheumatology.  37:2331-2340. 2018
    2018 Opioids vs nonopioids for chronic back, hip, or knee painJournal of the American Medical Association.  320:508. 2018
    2018 An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical ApproachesThe Permanente Journal.  22. 2018
    2018 Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitorsAnnals of the Rheumatic Diseases.  77:1012-1016. 2018
    2018 Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for CliniciansDrug Safety.  41:545-553. 2018
    2018 Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or EtanerceptPatient.  11:361-369. 2018
    2018 Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis.Rheumatology and Therapy.  5:283-291. 2018
    2018 Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patientsArthritis Research.  20. 2018
    2018 Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical TrialJournal of Bone and Mineral Research.  33:763-772. 2018
    2018 Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid ArthritisArthritis Care and Research.  70:679-684. 2018
    2018 Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysisPLoS ONE.  13. 2018
    2018 Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoidsAnnals of the Rheumatic Diseases.  77:644-649. 2018
    2018 ReplyArthritis and Rheumatology.  70:795-796. 2018
    2018 Defining and characterizing sustained remission in patients with rheumatoid arthritisClinical Rheumatology.  37:885-893. 2018
    2018 Use of Scribes for Documentation Assistance in Rheumatology and Endocrinology Clinics: Impact on Clinic Workflow and Patient and Physician SatisfactionJCR: Journal of Clinical Rheumatology.  24:116-121. 2018
    2018 Effectiveness and safety of tofacitinib in rheumatoid arthritis: A cohort studyArthritis Research.  20. 2018
    2018 Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based studyAnnals of the Rheumatic Diseases.  77:386-392. 2018
    2018 Hip fracture trends in the United States, 2002 to 2015Osteoporosis International.  29:717-722. 2018
    2018 Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-α-directed therapy for inflammatory bowel diseaseAmerican Journal of Gastroenterology.  113:405-417. 2018
    2018 Advancing the Science and Practice of Medication AdherenceJournal of General Internal Medicine.  33:216-222. 2018
    2018 Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritisSeminars in Arthritis and Rheumatism.  47:472-477. 2018
    2018 Just the FRAX: Management of Glucocorticoid-Induced OsteoporosisGastroenterology.  154:748-750. 2018
    2018 ReplyArthritis and Rheumatology.  70:320. 2018
    2018 Assessing a novel way to measure step count while walking using a custom mobile phone applicationPLoS ONE.  13. 2018
    2018 Development of algorithms for identifying fatal cardiovascular disease in Medicare claimsPharmacoepidemiology and Drug Safety2018
    2018 Incidence and prevalence of axial spondyloarthritis: Methodologic challenges and gaps in the literatureClinical and Experimental Rheumatology.  36:263-274. 2018
    2018 Lipid management among individuals with inflammatory arthritis in the national REasons for geographic and racial differences in stroke (REGARDS) cohortJournal of International Medical Research.  46:62-69. 2018
    2018 Routine use of quantitative disease activity measurements among us rheumatologists: Implications for treat-to-target management strategies in rheumatoid arthritisJournal of Rheumatology.  45:40-44. 2018
    2017 Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatmentArthritis Research.  19. 2017
    2017 Studies with herpes zoster vaccines in immune compromised patientsExpert Review of Vaccines.  16:1217-1230. 2017
    2017 Critical outcomes in longitudinal observational studies and registries in patients with rheumatoid arthritis: An OMERACT special interest group reportJournal of Rheumatology.  44:1894-1898. 2017
    2017 Herpes Zoster as a Risk Factor for Incident Giant Cell ArteritisArthritis and Rheumatology.  69:2351-2358. 2017
    2017 Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee ArthroplastyArthritis Care and Research.  69:1845-1854. 2017
    2017 Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research RegistryChest.  152:1120-1127. 2017
    2017 Serious Infections in Childhood-Onset Systemic Lupus Erythematosus: Using Administrative Claims Data to Investigate Disease OutcomesArthritis Care and Research.  69:1617-1619. 2017
    2017 Is gout a risk equivalent to diabetes for stroke and myocardial infarction? A retrospective claims database studyArthritis Research.  19. 2017
    2017 Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant TherapyArthritis and Rheumatology.  69:1960-1968. 2017
    2017 Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid ArthritisArthritis Care and Research.  69:1526-1534. 2017
    2017 The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trialOsteoporosis International.  28:3061-3066. 2017
    2017 The effects of a patient activation intervention on smoking and excessive drinking cessations: results from the PAADRN randomized controlled trialOsteoporosis International.  28:3055-3060. 2017
    2017 A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: Post-hoc results from the certolizumab pegol phase 4 PREDICT trialArthritis Research.  19. 2017
    2017 Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United StatesArthritis and Rheumatology.  69:1733-1740. 2017
    2017 Stakeholders' views on data sharing in multicenter studiesJournal of Comparative Effectiveness Research.  6:537-547. 2017
    2017 Erratum to: Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study (Osteoporosis International, (2017), 28, 8, (2495-2503), 10.1007/s00198-017-4073-5)Osteoporosis International.  28:2505. 2017
    2017 Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor–Alpha Experienced Rheumatoid ArthritisClinical Therapeutics.  39:1680-1694.e2. 2017
    2017 Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trialsAnnals of the Rheumatic Diseases.  76:1253-1262. 2017
    2017 Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseasesJournal of Rheumatology.  44:1083-1087. 2017
    2017 Knee Pain and Structural Damage as Risk Factors for Incident Widespread Pain: Data From the Multicenter Osteoarthritis StudyArthritis Care and Research.  69:826-832. 2017
    2017 Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot studyOsteoporosis International.  1-9. 2017
    2017 Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: A retrospective claims analysisArthritis Research.  19. 2017
    2017 Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritisJournal of Medical Economics (JME).  20:464-473. 2017
    2017 Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritisClinical and Experimental Rheumatology.  35:0390-0400. 2017
    2017 Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.Clinical and Experimental Rheumatology.  35:390-400. 2017
    2017 Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis c virus infectionJournal of Rheumatology.  44:565-570. 2017
    2017 Improving medical record retrieval for validation studies in Medicare dataPharmacoepidemiology and Drug Safety.  26:393-401. 2017
    2017 Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et alArthritis and Rheumatology.  69:863-865. 2017
    2017 Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetesBMC Cardiovascular Disorders.  17. 2017
    2017 Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertisingArthritis Research.  19. 2017
    2017 Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid ArthritisArthritis Care and Research.  69:313-322. 2017
    2017 The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insightsPharmacoepidemiology and Drug Safety.  26:310-319. 2017
    2017 Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinibClinical Rheumatology.  36:683-688. 2017
    2017 Herpes Zoster and the Risk of Stroke in Patients With Autoimmune DiseasesArthritis and Rheumatology.  69:439-446. 2017
    2017 Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programmeClinical and Experimental Rheumatology.  35:614-622. 2017
    2017 Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults secondary analysis of a randomized clinical trialJAMA Internal Medicine.  177:67-76. 2017
    2017 Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled TrialArthritis and Rheumatology.  69:46-57. 2017
    2016 A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention materialContemporary Clinical Trials Communications.  4:14-24. 2016
    2016 Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE studyLancet.  388:2763-2774. 2016
    2016 Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medicationClinicoEconomics and Outcomes Research.  8:707-715. 2016
    2016 Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registryArthritis Research.  18. 2016
    2016 Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid ArthritisArthritis Care and Research.  68:1751-1757. 2016
    2016 Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998-2009The Permanente Journal.  20:4-12. 2016
    2016 Usability and workflow evaluation of “RhEumAtic disease activity” (READY): A mobile application for rheumatology patients and providersApplied Clinical Informatics.  7:1007-1024. 2016
    2016 Adherence and persistence with methotrexate in rheumatoid arthritis: A systematic reviewJournal of Rheumatology.  43:1997-2009. 2016
    2016 Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic TreatmentsArthritis and Rheumatology.  68:2612-2617. 2016
    2016 Erratum: Corrigendum to “Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases” (Clinical Therapeutics (2016) 38(6) (1451–1463)(S0149291816301849)(10.1016/j.clinthera.2016.03.038))Clinical Therapeutics.  38:2506-2507. 2016
    2016 Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritisOsteoporosis International.  27:3239-3249. 2016
    2016 Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African AmericansArthritis Research.  18. 2016
    2016 Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort StudyArthritis and Rheumatology.  68:2403-2411. 2016
    2016 Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  75:1813-1818. 2016
    2016 Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritisAnnals of the Rheumatic Diseases.  75:1757-1762. 2016
    2016 Linkage of a Population-Based Cohort with Primary Data Collection to Medicare ClaimsAmerican Journal of Epidemiology.  184:532-544. 2016
    2016 Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  75:1843-1847. 2016
    2016 Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritisBMC Musculoskeletal Disorders.  17. 2016
    2016 The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritisArthritis Research.  18. 2016
    2016 Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patientsPediatric Rheumatology.  14. 2016
    2016 Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care SettingThe Permanente Journal.  20:4-10. 2016
    2016 Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein–Enriched Serum in Rheumatoid ArthritisArthritis and Rheumatology.  68:2099-2105. 2016
    2016 Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) StudyControlled Clinical Trials.  50:106-115. 2016
    2016 Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for VaccinationArthritis and Rheumatology.  68:2328-2337. 2016
    2016 Effects of a DXA result letter on satisfaction, quality of life, and osteoporosis knowledge: A randomized controlled trialBMC Musculoskeletal Disorders.  17. 2016
    2016 A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis studyContemporary Clinical Trials Communications.  3:32-38. 2016
    2016 Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid ArthritisAdvances in Therapy.  33:1347-1359. 2016
    2016 What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective StudyJournal of Bone and Mineral Research.  31:1500-1503. 2016
    2016 Survival rates of cancer patients with and without rheumatic disease: A retrospective cohort analysisBMC Cancer.  16. 2016
    2016 Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication usePharmacoepidemiology and Drug Safety.  25:827-835. 2016
    2016 Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back PainArthritis and Rheumatology.  68:1669-1676. 2016
    2016 Agreement between rheumatologist and patient-reported adherence to methotrexate in a US rheumatoid arthritis registryJournal of Rheumatology.  43:1027-1029. 2016
    2016 Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry.Rheumatology and Therapy.  3:103-115. 2016
    2016 Initial Experience with Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination with Conventional Synthetic DMARDs in 2 US Health Care Claims DatabasesClinical Therapeutics.  38:1451-1463. 2016
    2016 Reenergizing Research While Improving Patient CareProvider.  42. 2016
    2016 Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abataceptBMC Musculoskeletal Disorders.  17. 2016
    2016 Tofacitinib, an oral Janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical development programmeAnnals of the Rheumatic Diseases.  75:831-841. 2016
    2016 Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendationsArthritis Research.  18. 2016
    2016 Association of Triple Therapy with Improvement in Cholesterol Profiles over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis TrialArthritis and Rheumatology.  68:577-586. 2016
    2016 Comparative effectiveness of etanercept and adalimumab in patient reported outcomes and injection-related tolerabilityPLoS ONE.  11. 2016
    2016 Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: Data from the National Veterans Health AdministrationAnnals of the Rheumatic Diseases.  75:341-347. 2016
    2016 Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancerJAMA Dermatology.  152:164-172. 2016
    2016 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis and Rheumatology.  68:1-26. 2016
    2016 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis and Rheumatology.  68:1-26. 2016
    2016 Association of reduced eGFR and albuminuria with serious fall injuries among older adultsClinical Journal of the American Society of Nephrology.  11:1236-1243. 2016
    2016 Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in MedicareArthritis and Rheumatology.  68:56-66. 2016
    2016 Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents.J Psoriasis Psoriatic Arthritis.  1:128-137. 2016
    2016 Risk of Subsequent Infection among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic DrugsArthritis and Rheumatology.  68:67-76. 2016
    2015 A randomized trial comparing disease activity measures for the assessment and prediction of response in rheumatoid arthritis patients initiating certolizumab pegolArthritis and Rheumatology.  67:3104-3112. 2015
    2015 Herpes Zoster Reactivation in Patients with Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic DrugsArthritis Care and Research.  67:1671-1678. 2015
    2015 The Risk for Cardiovascular Events Associated with Hyperlipdemia among Patients with and Without Rheumatoid Arthritis.Journal of Arthritis.  4. 2015
    2015 The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare populationBritish Journal of Clinical Pharmacology.  80:1447-1457. 2015
    2015 Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor aα agents, a retrospective cohort studyArthritis Research.  17. 2015
    2015 Bone mineral density as a predictor of subsequent wrist fractures: Findings from the women's health initiative studyJournal of Clinical Endocrinology and Metabolism.  100:4315-4324. 2015
    2015 Effectiveness and costs of biologics in veterans with rheumatoid arthritisThe American journal of pharmacy benefits.  7:280-289. 2015
    2015 Methotrexate Adherence Questionnaire: a New Tool to Assess Adherence in Patients Treated with Methotrexate.Value in Health.  18:A714-A715. 2015
    2015 Optimal Use of Available Claims to Identify a Medicare Population Free of Coronary Heart DiseaseAmerican Journal of Epidemiology.  182:808-819. 2015
    2015 Wrist Fracture and Risk of Subsequent Fracture: Findings from the Women's Health Initiative StudyJournal of Bone and Mineral Research.  30:2086-2095. 2015
    2015 Analysis of osteoporosis treatment patterns with bisphosphonates and outcomes among postmenopausal veteransBONE.  78:174-185. 2015
    2015 Heterogeneous disease trajectories explain variable radiographic, function and quality of life outcomes in the Canadian Early Arthritis Cohort (CATCH)PLoS ONE.  10. 2015
    2015 The validity of claims-based algorithms to identify serious hypersensitivity reactions and osteonecrosis of the jawPLoS ONE.  10. 2015
    2015 Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in crohn's diseaseClinical Gastroenterology and Hepatology.  13:1293-1301.e5. 2015
    2015 Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: A retrospective cohort studyArthritis Research2015
    2015 An internet-based controlled trial aimed to improve osteoporosis prevention among chronic glucocorticoid usersJournal of Rheumatology.  42:1478-1483. 2015
    2015 Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: A substudyArthritis Care and Research.  67:929-939. 2015
    2015 Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured populationJournal of Managed Care Pharmacy.  21:318-328. 2015
    2015 DXA utilization between 2006 and 2012 in commercially insured younger postmenopausal womenJournal of Clinical Densitometry.  18:145-149. 2015
    2015 Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: A consortium of rheumatology researchers of North America registry studyArthritis and Rheumatology.  67:1995-2003. 2015
    2015 Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis PatientsArthritis Care and Research.  67:1345-1353. 2015
    2015 Disease activity in rheumatoid arthritis and the risk of cardiovascular eventsArthritis and Rheumatology.  67:1449-1455. 2015
    2015 Fractures and mortality in relation to different osteoporosis treatmentsClinical and Experimental Rheumatology.  33:302-309. 2015
    2015 Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patientsArthritis Care and Research.  67:624-632. 2015
    2015 Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare systemJournal of Rheumatology.  42:504-512. 2015
    2015 Mortality associated with medical therapy versus elective colectomy in ulcerative colitis a cohort studyAnnals of Internal Medicine.  163:262-270. 2015
    2015 Proceedings from the American College of Rheumatology Reproductive Health Summit: The management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseasesArthritis Care and Research.  67:313-325. 2015
    2015 ReplyArthritis Care and Research.  67:1041-1042. 2015
    2015 Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumabArthritis and Rheumatology.  67:1456-1464. 2015
    2015 Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapyArthritis Care and Research.  67:731-736. 2015
    2015 Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sourcesSeminars in Arthritis and Rheumatism.  44:381-388. 2015
    2015 Validation study of medicare claims to identify older US adults with CKD using the reasons for geographic and racial differences in stroke (REGARDS) studyAmerican Journal of Kidney Diseases.  65:249-258. 2015
    2014 Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: Persistent benefits. Data from the Corrona registryAnnals of the Rheumatic Diseases2014
    2014 The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritisPostgraduate Medical Journal.  90:722-729. 2014
    2014 Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: Results of the SAfety assessment of biologic ThERapy (SABER) studyAnnals of the Rheumatic Diseases.  73:1942-1948. 2014
    2014 The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spineJournal of Bone and Mineral Research.  29:2520-2526. 2014
    2014 Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United StatesArthritis Care and Research.  66:1604-1611. 2014
    2014 Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritisJournal of Rheumatology.  41:1935-1943. 2014
    2014 Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitorsJournal of Rheumatology.  41:2078-2084. 2014
    2014 Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugsArthritis Research.  16. 2014
    2014 Estimating effectiveness and cost of biologics for rheumatoid arthritis: Application of a validated algorithm to commercial insurance claimsClinical Therapeutics.  36:996-1004. 2014
    2014 Claims-based algorithms for identifying Medicare beneficiaries at high estimated risk for coronary heart disease events: A cross-sectional studyBMC Health Services Research.  14. 2014
    2014 Design characteristics of the CORRONA CERTAIN study: A comparative effectiveness study of biologic agents for rheumatoid arthritis patientsBMC Musculoskeletal Disorders.  15. 2014
    2014 Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiariesBMC Musculoskeletal Disorders.  15. 2014
    2014 Death, debility, and destitution following hip fractureJournals of Gerontology, Series A.  69 A:346-353. 2014
    2014 Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapyAnnals of the Rheumatic Diseases2014
    2014 Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugsSeminars in Arthritis and Rheumatism.  43:489-497. 2014
    2014 Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatmentJournal of Rheumatology.  41:216-226. 2014
    2014 Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: Results from the treatment of early aggressive rheumatoid arthritis trialPharmacogenomics Journal.  14:48-53. 2014
    2014 High plasma levels of vitamin C and E are associated with incident radiographic knee osteoarthritisOsteoarthritis and Cartilage.  22:190-196. 2014
    2014 Use of health plan combined with registry data to predict clinical trial recruitmentClinical Trials.  11:96-101. 2014
    2014 A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumabAnnals of the Rheumatic Diseases.  73:1429-1430. 2014
    2014 An evaluation of clinical risk factors for estimating fracture risk in postmenopausal osteoporosis using an electronic medical record databaseOsteoporosis International.  26:581-587. 2014
    2014 Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral researchJournal of Bone and Mineral Research.  29:1-23. 2014
    2014 Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the veterans health administrationJCR: Journal of Clinical Rheumatology.  20:357-362. 2014
    2014 Comparative effectiveness of infliximab and adalimumab for crohn's diseaseClinical Gastroenterology and Hepatology.  12:811-817.e3. 2014
    2014 Effect of self-referral on bone mineral density testing and osteoporosis treatmentMedical Care.  52:743-750. 2014
    2014 Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritisAnnals of the Rheumatic Diseases.  73:785-786. 2014
    2014 Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasisJournal of the European Academy of Dermatology and Venereology.  28:1380-1387. 2014
    2014 International management of bone health in glucocorticoid-exposed individuals in the observational GLOW studyOsteoporosis International.  26:419-420. 2014
    2014 Linkage of a de-identified united states rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness researchArthritis Care and Research.  66:1790-1798. 2014
    2014 ReplyArthritis Care and Research.  66:1271-1272. 2014
    2014 Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritisArthritis Care and Research.  66:990-997. 2014
    2014 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-Label, longterm extension studiesJournal of Rheumatology.  41:837-852. 2014
    2014 The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  73:1301-1308. 2014
    2014 Trends in the utilization and outcomes of medicare patients hospitalized for hip fracture, 2000-2008Journal of Aging and Health.  26:360-379. 2014
    2014 Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritisJournal of Medical Economics (JME).  17:555-566. 2014
    2014 Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone massOsteoporosis International.  25:317-324. 2014
    2014 Vaccinations for rheumatoid arthritisCurrent Rheumatology Reports.  16. 2014
    2014 Validity of claims-based stroke algorithms in contemporary medicare data: Reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claimsCirculation: Cardiovascular Quality and Outcomes.  7:611-619. 2014
    2013 The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factorAnnals of the Rheumatic Diseases2013
    2013 Commentary: Measuring quality of care in osteoporosisCurrent Osteoporosis Reports.  11:338-340. 2013
    2013 Commentary: The five ws of a fracture liaison service: Why, who, what, where, and how? in osteoporosis, we reap what we sowCurrent Osteoporosis Reports.  11:365-368. 2013
    2013 Epidemiologic research of invasive fungal infections using large healthcare databasesCurrent Fungal Infection Reports.  7:320-325. 2013
    2013 Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonistAnnals of the Rheumatic Diseases.  72:1813-1818. 2013
    2013 Tumor necrosis factor, tuberculosis, testing, and treatment: Teeing up the questionsArthritis Care and Research.  65:1719-1721. 2013
    2013 Tumor necrosis factor, tuberculosis, testing, and treatment: teeing up the questions.Arthritis Care and Research.  65:1719-1721. 2013
    2013 Using registries to identify adverse events in rheumatic diseasesPediatrics.  132. 2013
    2013 Challenges in defining quality of care for glucocorticoid-induced osteoporosis: Defending good against perfectJournal of Rheumatology.  40:1640-1642. 2013
    2013 Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia ® (denosumab) for the treatment of postmenopausal osteoporosisPharmacoepidemiology and Drug Safety.  22:1107-1114. 2013
    2013 Multimodal intervention to improve osteoporosis care in home health settings: Results from a cluster randomized trialOsteoporosis International.  24:2555-2560. 2013
    2013 Patient perspectives on achieving treat-to-target goals: A critical examination of patient-reported outcomesArthritis Care and Research.  65:1707-1712. 2013
    2013 Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patientsSeminars in Arthritis and Rheumatism.  43:137-143. 2013
    2013 Identifying newly approved medications in Medicare claims data: A case study using tocilizumabPharmacoepidemiology and Drug Safety.  22:1214-1221. 2013
    2013 ReplyAmerican Journal of Ophthalmology.  156:408. 2013
    2013 Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: Results from a two-year randomized, double-blind trialArthritis and Rheumatism.  65:1985-1994. 2013
    2013 Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009Pharmacoepidemiology and Drug Safety.  22:842-849. 2013
    2013 Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009Journal of Rheumatology.  40:1218-1225. 2013
    2013 Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseasesArthritis Care and Research.  65:1085-1094. 2013
    2013 Osteoporosis medication adherence: Physician perceptions vs. patients' utilizationBONE.  55:1-6. 2013
    2013 Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: A one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study)Clinical and Experimental Rheumatology.  31:358-364. 2013
    2013 Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: Results from the treatment of early rheumatoid arthritis trialArthritis and Rheumatism.  65:1430-1438. 2013
    2013 Brief report: Incidence of selected opportunistic infections among children with juvenile idiopathic arthritisArthritis and Rheumatism.  65:1384-1389. 2013
    2013 Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: Results from the TEAR trialJournal of Rheumatology.  40:572-578. 2013
    2013 New methods for determining comparative effectiveness in rheumatoid arthritisCurrent Opinion in Rheumatology.  25:325-333. 2013
    2013 Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritisCurrent Opinion in Rheumatology.  25:384-390. 2013
    2013 Development of a Multi-Biomarker Disease Activity Test for Rheumatoid ArthritisPLoS ONE.  8. 2013
    2013 A close examination of healthcare expenditures related to fracturesJournal of Bone and Mineral Research.  28:816-820. 2013
    2013 Association between anti-TNF-α therapy and interstitial lung diseasePharmacoepidemiology and Drug Safety.  22:394-402. 2013
    2013 Performance of FRAX in a cohort of community-dwelling, ambulatory older men: The Osteoporotic Fractures in Men (MrOS) studyOsteoporosis International.  24:1185-1193. 2013
    2013 Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims dataArthritis Research.  15. 2013
    2013 Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zosterJournal of the American Medical Association.  309:887-895. 2013
    2013 Magnitude and consequences of misclassification of incident hip fractures in large cohort studies: The Study of Osteoporotic Fractures and Medicare claims dataOsteoporosis International.  24:801-810. 2013
    2013 Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritisJournal of Rheumatology.  40:127-136. 2013
    2013 Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting SystemArthritis Care and Research.  65:235-243. 2013
    2013 Cardiovascular risk in rheumatoid arthritis: Comparing tnf-α blockade with nonbiologic DMARDsAmerican Journal of Medicine.  126:730.e9-730.e17. 2013
    2013 Generic alendronate use among medicare beneficiaries: Are part d data complete?Pharmacoepidemiology and Drug Safety.  22:55-63. 2013
    2013 Initiation of anti-TNF therapy and the risk of optic neuritis: From the safety assessment of biologic ThERapy (SABER) studyAmerican Journal of Ophthalmology.  155:183-189.e1. 2013
    2013 Low hemoglobin levels and recurrent falls in U.S. Men and Women: Prospective findings from the REasons for Geographic and racial differences in stroke (REGARDS) cohortAmerican Journal of the Medical Sciences.  345:446-454. 2013
    2013 Mycobacterial diseases and antitumour necrosis factor therapy in USAAnnals of the Rheumatic Diseases.  72:37-42. 2013
    2013 Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritisClinical Therapeutics.  35. 2013
    2013 The PAADRN Study: A design for a randomized controlled practical clinical trial to improve bone healthControlled Clinical Trials.  34:90-100. 2013
    2013 Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare programArthritis Care and Research.  65:1743-1751. 2013
    2013 Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseasesArthritis and Rheumatism.  65:48-58. 2013
    2013 Using tablet computers compared to interactive voice response to improve subject recruitment in osteoporosis pragmatic clinical trials: Feasibility, satisfaction, and sample sizePatient Preference and Adherence.  7:517-523. 2013
    2012 A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal womenJournal of Bone and Mineral Research.  27:2603-2610. 2012
    2012 Association between anti-TNF-α therapy and all-cause mortalityPharmacoepidemiology and Drug Safety.  21:1311-1320. 2012
    2012 Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational dataArthritis Care and Research.  64:1855-1863. 2012
    2012 Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritisArthritis Care and Research.  64:1819-1828. 2012
    2012 Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritisArthritis Care and Research.  64:1804-1810. 2012
    2012 Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activityArthritis Care and Research.  64:1794-1803. 2012
    2012 Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United StatesControlled Clinical Trials.  33:1211-1216. 2012
    2012 Recent trends in hip fracture rates by race/ethnicity among older US adultsJournal of Bone and Mineral Research.  27:2325-2332. 2012
    2012 Postherpetic neuralgia after herpes zoster vaccination - ReplyJournal of the American Medical Association.  308:1427-1428. 2012
    2012 Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high-versus lower-risk rheumatoid arthritis patientsArthritis Care and Research.  64:1480-1489. 2012
    2012 A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trialArthritis and Rheumatism.  64:2824-2835. 2012
    2012 Defining physiologically "normal" vitamin D in African AmericansOsteoporosis International.  23:2283-2291. 2012
    2012 Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapyArthritis Care and Research.  64:1282-1291. 2012
    2012 Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatmentArthritis and Rheumatism.  64:2773-2780. 2012
    2012 Association between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection among Older Patients with Selected Immune-Mediated DiseasesJournal of the American Medical Association.  308:43-49. 2012
    2012 Management of osteoporosis among the elderly with other chronic medical conditionsDrugs and Aging.  29:549-564. 2012
    2012 Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare populationArthritis Care and Research.  64:1054-1060. 2012
    2012 Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: A post-hoc analysis of the RAPID 1 trialJournal of Rheumatology.  39:1326-1333. 2012
    2012 Association of intact parathyroid hormone levels with subsequent hip BMD loss: The Osteoporotic Fractures in Men (MrOS) studyJournal of Clinical Endocrinology and Metabolism.  97:1937-1944. 2012
    2012 Malignancy validation in a United States registry of rheumatoid arthritis patientsBMC Musculoskeletal Disorders.  13. 2012
    2012 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care and Research.  64:635-639. 2012
    2012 Comparative safety of infliximab and etanercept on the risk of serious infections: Does the association vary by patient characteristics?Pharmacoepidemiology and Drug Safety.  21:524-534. 2012
    2012 Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year.Arthritis Care and Research.  64:658-667. 2012
    2012 Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapyApplied Health Economics and Health Policy.  10:163-173. 2012
    2012 Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changesJournal of Bone and Mineral Research.  27:858-864. 2012
    2012 Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseasesArthritis Care and Research.  64:612-615. 2012
    2012 Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health planBONE.  50:870-875. 2012
    2012 Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendationsArthritis and Rheumatism.  64:630-638. 2012
    2012 Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: The ROSE studyAnnals of the Rheumatic Diseases.  71:198-205. 2012
    2012 In responseEmerging Infectious Diseases.  18:361. 2012
    2012 Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: Exploratory analyses from the TEMPO trialAnnals of the Rheumatic Diseases.  71:206-212. 2012
    2012 Evaluating comorbidity scores based on health service expendituresMedicare & medicaid research review.  2. 2012
    2012 Improving osteoporosis care in high-risk home health patients through a high-intensity interventionControlled Clinical Trials.  33:206-212. 2012
    2012 Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.Arthritis and Rheumatism.  64:1263-1271. 2012
    2012 ReplyArthritis Care and Research.  64:157-158. 2012
    2012 Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 ReceptorClinical Therapeutics.  34. 2012
    2012 Validation of Diagnostic Codes for Subtrochanteric, Diaphyseal, and Atypical Femoral Fractures Using Administrative Claims DataJournal of Clinical Densitometry.  15:92-102. 2012
    2011 Initiation of tumor necrosis factor-αantagonists and the risk of hospitalization for infection in patients with autoimmune diseasesJournal of the American Medical Association.  306:2331-2339. 2011
    2011 Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practiceArthritis Care and Research.  63:1680-1690. 2011
    2011 Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: A retrospective pooled analysisRheumatology.  50:2223-2232. 2011
    2011 Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohortArthritis Care and Research.  63:1672-1679. 2011
    2011 Study design for a comprehensive assessment of biologic safety using multiple healthcare data systemsPharmacoepidemiology and Drug Safety.  20:1199-1209. 2011
    2011 Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patientsPharmacoepidemiology and Drug Safety.  20:1150-1158. 2011
    2011 The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: A longitudinal observational studyArthritis Research.  13. 2011
    2011 Changes in cotherapies after initiation of disease - Modifying antirheumatic drug therapy in patients with rheumatoid arthritisArthritis Care and Research.  63:1415-1424. 2011
    2011 Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritisArthritis Research.  13. 2011
    2011 Geographic distribution of endemic fungal infections among older persons, United StatesEmerging Infectious Diseases.  17:1664-1669. 2011
    2011 Developing a construct to evaluate flares in rheumatoid arthritis: A conceptual report of the OMERACT RA Flare Definition Working GroupJournal of Rheumatology.  38:1745-1750. 2011
    2011 Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: An analysis of individual patient-level dataArthritis and Rheumatism.  63:2203-2208. 2011
    2011 Erratum: Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research (Journal of Bone and Mineral Research (2010) 25 (2267-2294))Journal of Bone and Mineral Research.  26:1987. 2011
    2011 Improving osteoporosis care through multimodal interventions: Insights from the University of Alabama at Birmingham Center for Education and Research on TherapeuticsOsteoporosis International.  22. 2011
    2011 The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsAnnals of the Rheumatic Diseases.  70:1401-1406. 2011
    2011 Consistency of knee pain and risk of knee replacement: The multicenter osteoarthritis studyJournal of Rheumatology.  38:1390-1395. 2011
    2011 Corrigendum to "Cost burden of second fracture in the US Health System" [Bone 48 (2011) 828-836]BONE.  48:1429. 2011
    2011 Medical costs of osteoporosis in the elderly Medicare populationOsteoporosis International.  22:1835-1844. 2011
    2011 Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: Post-hoc analysis of a randomized controlled trialJournal of Rheumatology.  38:990-996. 2011
    2011 Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of CareClinical Therapeutics.  33:679-707. 2011
    2011 High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  70:785-791. 2011
    2011 Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trialsMedical Care.  49:427-435. 2011
    2011 Response to Letter to Editor on validation study identifying bacterial infections in rheumatoid arthritis patientsJournal of Clinical Epidemiology.  64:573. 2011
    2011 Cost burden of second fracture in the US Health SystemBONE.  48:828-836. 2011
    2011 Erratum: Clinical and demographic factors associated with fractures among older Americans (Osteoporosis International DOI: 10.1007/s00198-010-1300-8)Osteoporosis International.  22:1275-1276. 2011
    2011 The relationship between bisphosphonate adherence and fracture: Is it the behavior or the medication? Results from the placebo arm of the fracture intervention trialJournal of Bone and Mineral Research.  26:683-688. 2011
    2011 Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  70:576-582. 2011
    2011 TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritisMedicine.  90:139-145. 2011
    2011 The incidence of gastrointestinal perforations among rheumatoid arthritis patientsArthritis and Rheumatism.  63:346-351. 2011
    2011 Clinical and demographic factors associated with fractures among older AmericansOsteoporosis International.  22:1263-1274. 2011
    2011 Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologicsCurrent Medical Research and Opinion.  27:71-78. 2011
    2011 Official Positions for FRAX® Clinical Regarding International Differences. From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®Journal of Clinical Densitometry.  14:240-262. 2011
    2011 Which fractures are most attributable to osteoporosis?Journal of Clinical Epidemiology.  64:46-53. 2011
    2010 Predicting hip and major osteoporotic fractures using administrative dataArchives of Internal Medicine -New Series-.  170:1940-1942. 2010
    2010 Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral ResearchJournal of Bone and Mineral Research.  25:2267-2294. 2010
    2010 Explaining the cardiovascular risk associated with rheumatoid arthritis: Traditional risk factors versus markers of rheumatoid arthritis severityAnnals of the Rheumatic Diseases.  69:1920-1925. 2010
    2010 Consistency of knee pain: Correlates and association with functionOsteoarthritis and Cartilage.  18:1250-1255. 2010
    2010 Converting modified Health Assessment Questionnaire (HAQ), multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patientsArthritis Care and Research.  62:1481-1488. 2010
    2010 Osteoporosis care in the United States after declines in reimbursements for DXAJournal of Clinical Densitometry.  13:352-360. 2010
    2010 Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosisOsteoporosis International.  21:1573-1584. 2010
    2010 Health services utilization after fractures: Evidence from MedicareJournals of Gerontology, Series A.  65 A:1012-1020. 2010
    2010 Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases.  69:1612-1617. 2010
    2010 The delivery of evidence-based preventive care for older Americans with arthritisArthritis Research.  12. 2010
    2010 Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US national osteoporosis foundation guidelinesJournal of Bone and Mineral Research.  25:1506-1511. 2010
    2010 Identifying types of nursing facility stays using medicare claims data: An algorithm and validationHealth Services and Outcomes Research Methodology.  10:100-110. 2010
    2010 Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologicsMedical Care.  48. 2010
    2010 Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: A review of the literature and a case reportSpecial Care in Dentistry.  30:77-82. 2010
    2010 Pre-radiographic MRI findings are associated with onset of knee symptoms: the most studyOsteoarthritis and Cartilage.  18:323-328. 2010
    2010 Vitamin D status and its associations with disease activity and severity in african americans with recent-onset rheumatoid arthritisJournal of Rheumatology.  37:275-281. 2010
    2010 Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activityArthritis Care and Research.  62:101-107. 2010
    2010 A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries1Seminars in Arthritis and Rheumatism.  40:2-14.e1. 2010
    2010 American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.Arthritis Care and Research.  62:1515-1526. 2010
    2010 Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomideAnnals of the Rheumatic Diseases.  69:43-47. 2010
    2010 High systemic bone mineral density increases the risk of incident knee OA and joint space narrowing, but not radiographic progression of existing knee OA: The MOST studyAnnals of the Rheumatic Diseases.  69:163-168. 2010
    2010 Is withholding osteoporosis medication after fracture sometimes rational? A Comparison of the risk for second fracture versus deathJournal of the American Medical Directors Association.  11:584-591. 2010
    2009 Health care expenditures associated with skeletal fractures among medicare beneficiaries, 1999-2005Journal of Bone and Mineral Research.  24:2050-2055. 2009
    2009 "pathologic" fractures: Should these be included in epidemiologic studies of osteoporotic fractures?Osteoporosis International.  20:1969-1972. 2009
    2009 Do physicians within the same practice setting manage osteoporosis patients similarly? Implications for implementation researchOsteoporosis International.  20:1921-1927. 2009
    2009 Skeletal health among African Americans with recent-onset rheumatoid arthritisArthritis Care and Research.  61:1379-1386. 2009
    2009 Quality health care gaps in osteoporosis: How can patients, providers, and the health system do a better job?Current Osteoporosis Reports.  7:27-34. 2009
    2009 Systemic Nonarticular Manifestations of Rheumatoid Arthritis: Focus on Inflammatory MechanismsSeminars in Arthritis and Rheumatism.  39:132-143. 2009
    2009 Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare dataOsteoporosis International.  20:1507-1515. 2009
    2009 The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United StatesOsteoporosis International.  20:1553-1561. 2009
    2009 Adherence to osteoporosis treatments: Room for improvementCurrent Opinion in Rheumatology.  21:356-362. 2009
    2009 RisedronatE and ALendronate intervention over three years (REALITY): Minimal differences in fracture risk reductionOsteoporosis International.  20:973-978. 2009
    2009 Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: A population-based cohort studyOsteoporosis International.  20:819-826. 2009
    2009 Management of osteoporosis among home health and long-term care patients with a prior fractureSouthern Medical Journal.  102:397-404. 2009
    2009 Improving the prediction of medication compliance: The example of bisphosphonates for osteoporosisMedical Care.  47:334-341. 2009
    2009 Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patientsJournal of Clinical Epidemiology.  62. 2009
    2009 Bridging the osteoporosis quality chasmJournal of Bone and Mineral Research.  24:3-7. 2009
    2009 Identification and validation of vertebral compression fractures using administrative claims dataMedical Care.  47:69-72. 2009
    2009 Population-based fracture risk assessment and osteoporosis treatment disparities by race and genderJournal of General Internal Medicine.  24:956-962. 2009
    2009 Validity of physician-reported hospitalized infections in a US arthritis registry.Rheumatology.  48:1269-1272. 2009
    2008 Tumor necrosis factor inhibitors and infection complicationsCurrent Rheumatology Reports.  10:383-389. 2008
    2008 Risk of hip fracture after bisphosphonate discontinuation: Implications for a drug holidayOsteoporosis International.  19:1613-1620. 2008
    2008 Muscle Mass Is More Strongly Related to Hip Bone Mineral Density Than Is Quadriceps Strength or Lower Activity Level in Adults Over Age 50 YearJournal of Clinical Densitometry.  11:503-510. 2008
    2008 Regional Variation in the Denial of Reimbursement for Bone Mineral Density Testing Among US Medicare BeneficiariesJournal of Clinical Densitometry.  11:568-574. 2008
    2008 Adaptation of bayesian data mining algorithms to longitudinal claims data: Coxib safety as an exampleMedical Care.  46:969-975. 2008
    2008 Benefit of adherence with bisphosphonates depends on age and fracture type: Results from an analysis of 101,038 new bisphosphonate usersJournal of Bone and Mineral Research.  23:1435-1441. 2008
    2008 Mortality and osteoporotic fractures: Is the link causal, and is it modifiable?Clinical and Experimental Rheumatology.  26. 2008
    2008 Mortality and osteoporotic fractures: is the link causal, and is it modifiable?Clinical and Experimental Rheumatology.  26:S125-S137. 2008
    2008 Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005Journal of Bone and Mineral Research.  23:1061-1067. 2008
    2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritisArthritis Care and Research.  59:762-784. 2008
    2008 Leg-length inequality is not associated with greater trochanteric pain syndromeArthritis Research.  10. 2008
    2008 Association of infections and tuberculosis with antitumor necrosis factor alpha therapyCurrent Opinion in Rheumatology.  20:320-326. 2008
    2008 Biologics and heart failure in rheumatoid arthritis: Are we any wiser?Current Opinion in Rheumatology.  20:327-333. 2008
    2008 Improving quality of care in osteoporosis: Opportunities and challengesCurrent Rheumatology Reports.  10:123-130. 2008
    2008 The epidemiology of glucocorticoid-associated adverse eventsCurrent Opinion in Rheumatology.  20:131-137. 2008
    2008 Association of health-related quality of life with dual use of prescription and over-the-counter nonsteroidal antiinflammatory drugsArthritis Care and Research.  59:227-233. 2008
    2007 Racial/ethnic disparities in patient-reported nonsteroidal antiinflammatory drug (NSAID) risk awareness, patient-doctor NSAID risk communication, and NSAID risk behaviorArthritis Care and Research.  57:1539-1545. 2007
    2007 Challenges in defining and improving osteoporosis quality of careClinical and Experimental Rheumatology.  25. 2007
    2007 Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonistsArthritis and Rheumatism.  56:4226-4227. 2007
    2007 Challenges in defining and improving osteoporosis quality of care.Clinical and Experimental Rheumatology.  25:142-146. 2007
    2007 Randomized Trial to Improve Fracture Prevention in Nursing Home ResidentsAmerican Journal of Medicine.  120:886-892. 2007
    2007 Greater Trochanteric Pain Syndrome: Epidemiology and Associated FactorsArchives of Physical Medicine and Rehabilitation.  88:988-992. 2007
    2007 Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fractureOsteoporosis International.  18:553-559. 2007
    2007 Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonistsArthritis and Rheumatism.  56:1125-1133. 2007
    2007 Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: A prospective randomized trialArchives of Internal Medicine -New Series-.  167:591-596. 2007
    2007 Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.Arthritis and Rheumatism.  57:343-346. 2007
    2007 Prevention and treatment of glucocorticoid-induced osteoporosisCurrent Osteoporosis Reports.  5:14-21. 2007
    2007 Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-α antagonistsRheumatology.  46:1688-1693. 2007
    2006 Osteoporosis in the home health care setting: A window of opportunity?Arthritis Care and Research.  55:971-975. 2006
    2006 Treatment of rheumatoid arthritisAmerican Journal of Health-System Pharmacy.  63:2451-2465. 2006
    2006 Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid usersPharmacoepidemiology and Drug Safety.  15:710-718. 2006
    2006 Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugsAmerican Journal of Health-System Pharmacy.  63:1837. 2006
    2006 Channeling and adherence with alendronate and risedronate among chronic glucocorticoid usersOsteoporosis International.  17:1268-1274. 2006
    2006 Trends in prevention of glucocorticoid-induced osteoporosisJournal of Rheumatology.  33:1651-1657. 2006
    2006 Population-based assessment of adverse events associated with long-term glucocorticoid useArthritis Care and Research.  55:420-426. 2006
    2006 Medication errors with the use of allopurinol and colchicine: A retrospective study of a national, anonymous internet-accessible error reporting systemJournal of Rheumatology.  33:562-566. 2006
    2006 Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophyAIDS Research and Human Retroviruses.  22:125-131. 2006
    2006 Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventionsPharmacoepidemiology and Drug Safety.  15:11-18. 2006
    2005 A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugsAmerican Journal of Managed Care.  11:537-543. 2005
    2005 Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patientsArthritis and Rheumatism.  52:2485-2494. 2005
    2005 Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: The impact of ethnic-specific normative dataJournal of the National Medical Association.  97:1155-1160. 2005
    2004 Swallowing difficulties from "DISH-phagia"Journal of Rheumatology.  31:2526-2527. 2004
    2004 Evaluating and improving the quality of care in rheumatic diseaseExpert Review of Pharmacoeconomics and Outcomes Research.  4:429-439. 2004
    2004 Vitamin D Intake Is Inversely Associated With Rheumatoid Arthritis: Results From the Iowa Women's Health StudyArthritis and Rheumatism.  50:72-77. 2004
    2003 Nonsteroidal Antiinflammatory Drug Toxicity Monitoring and Safety PracticesJournal of Rheumatology.  30:2680-2688. 2003
    2003 The Use of Glucocorticoids in Arthritis – 20 Clinical PearlsJournal of Musculoskeletal Medicine.  20:425-433. 2003
    1985 ReplyAmerican Journal of Ophthalmology.  99:220. 1985

    Chapter

    Year Title Altmetric
    2018 Studies of Biologicals 2018
    2009 Bisphosphonate Therapy for Osteoporosis 2009
    2008 Glucocorticoid-Induced Osteoporosis.  1135-1166. 2008
    2005 Prevention and Treatment 2005
    2004 Therapeutic Dictionary of Rheumatology and Immunology 2004
    2001 Glucocorticoid-induced osteoporosis.  140-145. 2001
    2000 New Biologics: Cytokines 2000

    Research Overview

  • Rheumatoid Arthritis
    Psoriatic Arthritis
    Ankylosing Spondylitis
    Osteoporosis
  • Principal Investigator On

  • Private Grant  awarded by AMGEN, INC. 2011 - 2024
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2016 - 2021
  • Harnessing PCORnet to Study Comparative Effectiveness and Safety of Biologic Therapies  awarded by PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE 2016 - 2020
  • Private Grant  awarded by CRESCENDO BIOSCIENCE, INC. 2018 - 2020
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2020
  • Private Grant  awarded by AMGEN, INC. 2015 - 2020
  • Private Grant  awarded by CRESCENDO BIOSCIENCE, INC. 2018 - 2020
  • Private Grant  awarded by CRESCENDO BIOSCIENCE, INC. 2015 - 2019
  • Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2014 - 2019
  • Arthritis Patient Partnership with Comparative Effectiveness Researchers (Arthritis Patient PoWER)  awarded by GLOBAL HEALTHY LIVING FOUNDATION 2015 - 2019
  • UAB Multidisciplinary Clinical Research Center - Project 2: Facilitating Treat-to-Target Using Novel Health Technology with Decision Support  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2019
  • Treatments Against RA and Effect of FDG PET-CT: The TARGET Trial  awarded by Brigham and Women's Hospital 2015 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2016 - 2019
  • Private Grant  awarded by RADIUS HEALTH 2018 - 2019
  • Private Grant  awarded by Genentech 2014 - 2019
  • Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-Management  awarded by University of North Carolina at Chapel Hill 2016 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2014 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2017 - 2018
  • Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis  awarded by Oregon Health & Science University 2016 - 2018
  • Privacy-Preserving Analytic and Data-Sharing Methods for Clinical and Patient-Powered Research Data Research Networks  awarded by HARVARD PILGRIM HEALTH CARE 2015 - 2017
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2017
  • Private Grant  awarded by Pfizer Pharmaceuticals 2009 - 2017
  • Centers of Research Translation (CoRT) - Project 4  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • Private Grant  awarded by CELGENE CORPORATION 2010 - 2017
  • Private Grant  awarded by Pfizer Pharmaceuticals 2014 - 2017
  • Making PROMISE Meaningful to Patients and Providers in Clinical Practice  awarded by Johns Hopkins University 2015 - 2016
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2013 - 2016
  • Patient Valued Comparative Effectiveness of Corticosteroids Versus Anti-TNF Alpha Therapy for Inflammatory Bowel Disease  awarded by University of Pennsylvania 2013 - 2016
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2016
  • Private Grant  awarded by AMGEN, INC. 2014 - 2016
  • A Pilot Study of the Safety and Effectiveness of the Live Zoster Vaccine in Anti-TNF Users  awarded by RHEUMATOLOGY RESEARCH FOUNDATION 2013 - 2016
  • Private Grant  awarded by CONSORTIUM OF RHEUMATOLOGY RESEARCHERS OF NORTH AMERICA, INC. 2008 - 2016
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2014 - 2016
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2012 - 2016
  • Private Grant  awarded by AMGEN, INC. 2014 - 2015
  • Private Grant  awarded by AMGEN, INC. 2012 - 2015
  • Private Grant  awarded by KNOLL PHARMACEUTICAL COMPANY 2007 - 2015
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2012 - 2015
  • Arthritis Patient Partnership With Comparative Effectiveness Researchers (AR-Power PPRN)  awarded by GLOBAL HEALTHY LIVING FOUNDATION 2014 - 2015
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2014 - 2015
  • Private Grant  awarded by UCB, INC. 2012 - 2015
  • Private Grant  awarded by Sanofi US Services Inc 2013 - 2015
  • Private Grant  awarded by Pfizer Pharmaceuticals 2013 - 2015
  • Private Grant  awarded by UCB, INC. 2012 - 2014
  • Longitudinal Comparative Effectiveness & Safety of Biologics in Autoimmunity  awarded by Agency for Healthcare Research and Quality/DHHS 2009 - 2014
  • Private Grant  awarded by Genentech 2012 - 2014
  • Private Grant  awarded by AMGEN, INC. 2014
  • Private Grant  awarded by Genentech 2007 - 2014
  • Private Grant  awarded by Pfizer Pharmaceuticals 2010 - 2014
  • Private Grant  awarded by INCYTE CORPORATION 2009 - 2014
  • Private Grant  awarded by ELI LILLY AND COMPANY 2011 - 2014
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2012 - 2014
  • Private Grant  awarded by Genentech 2011 - 2013
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2011 - 2013
  • Private Grant  awarded by Genentech 2011 - 2013
  • Private Grant  awarded by ACTURIAL RESEARCH CORPORATION 2013
  • Private Grant  awarded by Sanofi US Services Inc 2010 - 2013
  • Private Grant  awarded by ANOLINX, LLC 2011 - 2013
  • Private Grant  awarded by CONSORTIUM OF RHEUMATOLOGY RESEARCHERS OF NORTH AMERICA, INC. 2007 - 2013
  • Private Grant  awarded by Genentech 2012 - 2013
  • ACE Protocol #ARA06  awarded by Duke University 2009 - 2013
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2007 - 2013
  • Private Grant  awarded by ELI LILLY AND COMPANY 2008 - 2013
  • Private Grant  awarded by UCB PHARMA, INC. 2011 - 2013
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2010 - 2013
  • Private Grant  awarded by Genentech 2011 - 2013
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2008 - 2013
  • Private Grant  awarded by Centocor 2007 - 2013
  • Private Grant  awarded by UCB PHARMA, INC. 2011 - 2012
  • Coronary Heart Disease in Rheumatoid Arthritis  awarded by Arthritis Foundation 2011 - 2012
  • The TAKEOFF Trial: Clinical Trial Planning Grant  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2011 - 2012
  • Ethnic Differences in the Risk of Fracture and Vascular Disease  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2007 - 2012
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2007 - 2012
  • Private Grant  awarded by Pfizer Pharmaceuticals 2009 - 2012
  • Safety and Effectiveness of Herpes Zoster Vaccination in Rheumatoid Arthritis Patients  awarded by American College of Rheumatology 2011 - 2012
  • Private Grant  awarded by Genentech 2008 - 2012
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2010 - 2012
  • Private Grant  awarded by Genentech 2009 - 2012
  • Long Term Risks and Extra-Skeletal Benefits of Biologics  awarded by Duke (Doris) Charitable Foundation 2007 - 2012
  • Private Grant  awarded by Sanofi US Services Inc 2010 - 2011
  • Private Grant  awarded by Sanofi US Services Inc 2010 - 2011
  • Private Grant  awarded by AMGEN, INC. 2007 - 2011
  • Kaiser Permanente Autoimmune Disease Registry  awarded by Kaiser Permanente 2009 - 2011
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2009 - 2011
  • Private Grant  awarded by UCB PHARMA, INC. 2008 - 2011
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2007 - 2011
  • Private Grant  awarded by ABBOTT LABORATORIES 2007 - 2011
  • Private Grant  awarded by WYETH PHARMACEUTICALS, INC. 2008 - 2011
  • ACE - Switching Anti-TNF-a Agents in Patients with RA with an Inadequate Response to TNF-a Inhibition - ACE  awarded by Duke University 2009 - 2011
  • Private Grant  awarded by CRESCENDO BIOSCIENCE, INC. 2009 - 2010
  • Arthritis Foundation Investigator Award: Osteoporosis and Associated Stroke and MI in a Multi-Ethnic Cohort  awarded by Arthritis Foundation 2007 - 2010
  • Private Grant  awarded by AMGEN, INC. 2009 - 2010
  • Private Grant  awarded by Genentech 2007 - 2010
  • Investigator On

  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • INvestigations In Gout, Hyperuricemia, and ComorbidiTies (INSIGHT) Center of Research Translation (CORT) - Administrative Core  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2017 - 2022
  • Strengthening Translational Research in Diverse Enrollment (STRIDE)  awarded by UNIVERSITY OF MASSACHUSETTS (WORCESTER) 2016 - 2021
  • Multimorbidity in Rheumatoid Arthritis  awarded by American College of Rheumatology 2019 - 2020
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Promo/Dissemination Component  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation: Tech Developments Component  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • Rehabilitation Research Resource to Enhance Clinical Trials (REACT)  awarded by National Institute of Child Health and Human Development/NIH/DHHS 2015 - 2020
  • The Relationship of Disease Activity to Medication use in the RISE Registry  awarded by American College of Rheumatology 2017 - 2019
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2017 - 2019
  • UAB Multidisciplinary Clinical Research Center (P60)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2019
  • ACE Protocol ARA08: Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA)  awarded by University of California, San Francisco 2015 - 2019
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2016 - 2019
  • Outliers - Extreme Long-term Survivors with Metastatic Breast Cancer  awarded by University of Wisconsin-Madison 2018
  • Brain Thermometry: A Non-Invasive Method for Detecting Neuroinflammation in RA  awarded by RHEUMATOLOGY RESEARCH FOUNDATION 2016 - 2017
  • Centers of Research Translation (CoRT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2012 - 2017
  • UAB Deep South Arthritis and Musculoskeletal CERTs  awarded by Agency for Healthcare Research and Quality/DHHS 2011 - 2017
  • Private Grant  awarded by Janssen 2016 - 2017
  • Private Grant  awarded by ABBVIE INC 2016
  • Effectiveness of DiscontinuinG BisphosphonatEs Study (EDGE)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2016
  • Private Grant  awarded by AMGEN, INC. 2014 - 2015
  • Private Grant  awarded by AMGEN, INC. 2014 - 2015
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015
  • Burden of Osteoporosis and Low Bone Density in the United States  awarded by National Osteoporosis Foundation 2012 - 2014
  • NIAMS Multidiscipllinary Clinical Research Center  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2008 - 2014
  • NIAMS Multidiscipllinary Clinical Research Center - Project 4  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2008 - 2014
  • Private Grant  awarded by AMGEN, INC. 2013 - 2014
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC. 2012 - 2014
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2012 - 2013
  • Private Grant  awarded by ARDEA BIOSCIENCES, INC. 2011 - 2013
  • Does Aggressive Treatment in Early RA Reduce Biomarkers of Cardiovascular Risk?  awarded by University of California, Los Angeles 2010 - 2013
  • Private Grant  awarded by AMGEN, INC. 2012 - 2013
  • Deep South Musculoskeletal Certs (DSMC)  awarded by Agency for Healthcare Research and Quality/DHHS 2007 - 2012
  • Private Grant  awarded by AMGEN, INC. 2010 - 2012
  • Education And Training

  • Doctor of Medicine, Oregon Health Sciences University 1999
  • Master of Public Health, Oregon Health Sciences University 1999
  • Oregon Health Science University Hospital & Clinic, Internship 2000
  • Oregon Health Science University Hospital & Clinic, Residency 2002
  • UAB Hospital, Postdoctoral Fellowship 2005
  • Full Name

  • Jeffrey Curtis